Eric M Thompson, M.D.
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric M Thompson, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:54 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06639607 · PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and EpendymomaWashington University School of Medicine · suspended · Diffuse Midline Glioma, Diffuse Midline High-grade Glioma, Medulloblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)R01CA296813 · NCI · WASHINGTON UNIVERSITY · PI Eric Thompson · fiscal years 2025 to 2026Named on NCT06639607
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in diffuse midline glioma (dipg).